{"entity":{"id":"adavosertib","kind":"drug","name":"Adavosertib","aka":[],"tldr":"Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.","summary":"Adavosertib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in triple-negative breast cancer. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Adavosertib","url":"https://clinicaltrials.gov/search?intr=Adavosertib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03330847"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral serine/threonine kinase inhibitor","mechanism":"A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/adavosertib/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/"}]}}